Home Alzheimer’s Disease Response to Nivolumab in Metastatic Urothelial Cancer Is Enhanced by Eganelisib

Response to Nivolumab in Metastatic Urothelial Cancer Is Enhanced by Eganelisib

Eganelisib (IPI 549), a novel PI3K-y inhibitor, induced promising response rates when added to nivolumab (Opdivo) for the treatment of patients with metastatic urothelial carcinoma (mUC), according to results of a phase 2 trial.

“PD-1 inhibitors have demonstrated clinical benefit in metastatic urothelial carcinoma. However, clinical benefit remains low, particularly in PD-L1—low patients, who have [an average] overall response rate of only 16%,” study author Piotr Tomczak, of the Poznan University of Medical Sciences in Poznan, Poland, said in a presentation at the 2021 Genitourinary Cancers Symposium where the data were read out.

The MARIO-275 study (NCT03980041) included 49 patients with mUC who progressed on 1 or more platinum-based chemotherapy regimens and had no prior treatment with a checkpoint inhibitor. Study participants were stratified by baseline circulating monocytic…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments